

BUYTP: Rs 2,230 | ▲ 15%

L&T INFOTECH

IT Services

15 January 2020

Stellar show

L&T Infotech (LTI) reported 8.3% QoQ CC revenue growth in Q3FY20, well ahead of estimates. Operating margins also bettered our expectations at 16.2%. Revenue growth was broad-based across verticals and marked a resurgence among top clients. LTI won two large deals with aggregate TCV of US\$ 75mn+. Impressive revenues and a track record of big deal wins position LTI well to reclaim its industry-wide growth leadership. We thus raise our P/E multiple to 20x from 19.3x; on rollover we have a new Mar'21 TP of Rs 2,230 (vs. Rs 2,010).

Ruchi Burde research@bobcaps.in

Stellar growth: LTI reported 8.3% QoQ CC revenue growth, well ahead of our (3.4%) and street estimates. Even excluding the ~2% contribution from pass-through and inorganic revenues, the Q3 revenue growth was impressive. EBITDA at Rs 5.3bn (+13.2% QoQ, +3.6% YoY) was ~7% ahead of our forecast. But below-expected other income and forex gains led to largely inline net profits at Rs 3.8bn (+4.6% QoQ, +0.3% YoY).

Revenues broad-based across verticals and clients: Revenue growth was broad-based across verticals and marked a resurgence among top clients. Dollar revenue from the top 5/top 10/top 20 clients increased by 12.2%/11.5%/9.5% QoQ. Similarly, dollar revenue growth rebounded in the BFS (+11.3% QoQ) and Technology & Media (+8.4%) verticals which were under stress in recent quarters. Both segments saw ramp-up of recently won deals while BFS also benefited from strong recovery in a top account.

Optimistic BFS outlook: In contrast to peers, LTI shared optimistic BFS commentary, including growth visibility at its large BFS client. The company is well on track to meeting its guidance of double-digit FY20 revenue growth (our forecast stands at 13.6% YoY CC). Management reiterated its net margin guidance range of 14-15% which appears slightly demanding in our view.

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue (Rs mn)	73,064	94,458	1,07,103	1,22,099	1,36,908
EBITDA (Rs mn)	11,875	18,835	19,941	23,574	26,597
Adj. net profit (Rs mn)	11,124	15,157	14,971	17,837	19,538
Adj. EPS (Rs)	63.5	86.5	85.4	101.8	111.5
Adj. EPS growth (%)	(8.2)	36.1	(1.2)	19.1	9.5
Adj. ROAE (%)	31.8	34.6	28.1	28.4	26.6
Adj. P/E (x)	30.4	22.4	22.6	19.0	17.3
EV/EBITDA (x)	28.3	17.8	16.8	14.1	12.2

Source: Company, BOBCAPS Research

Ticker/Price	LTI IN/Rs 1,934
Market cap	US\$ 4.8bn
Shares o/s	175mn
3M ADV	US\$ 3.8mn
52wk high/low	Rs 2,003/Rs 1,436
Promoter/FPI/DII	75%/8%/10%

Source: NSE

STOCK PERFORMANCE



Source: NSE





FIG 1 - LARGE DEAL WINS A RECURRING FEATURE

Quarter	Large deal wins						
Dec-19	2 large deals with aggregate net new TCV of US\$ 75mn+						
Sep-19	3 new logos opened with aggregate net new TCV of US\$ 100mn						
Jun-19	New logo in the insurance vertical with TCV of US\$ 44mn						
	2 large deals with net new TCV of US\$ 100mn+						
	Deal 1: Multi-year multi-million-dollar deal for transforming global application						
Mar-19	operations of an engineering equipment manufacturer						
	 Deal 2: New logo opening with a large IT transformation deal in the insurance vertical 						
	Secured large deal for a payments company in the Nordic region as primary IT						
Dec-18	partner post vendor consolidation						
Sep-18	Secured a large deal for a global pharma company with net new TCV of US\$ 55mn						
	1 large deal with net new TCV of US\$ 50mn						
Jun-18	Multi-year multi-million-dollar deal in ERP, data and analytics with global						
	consumer and pharmaceutical conglomerate						
	DODGADC D						

Source: Company, BOBCAPS Research.

FIG 2 - SURGE IN REVENUE FROM TOP 5 CLIENTS





FIG 3 – BFS SAW STRONG GROWTH REBOUND



Source: Company, BOBCAPS Research

FIG 4 - MANAGEMENT ACKNOWLEDGED SCOPE TO IMPROVE MARGINS






FIG 5 – DEC'19 QUARTER PERFORMANCE

(Rs mn)	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Y ₀ Y (%)	Q ₀ Q (%)	9MFY20	9MFY19	Y ₀ Y (%)
Revenues (US\$ mn)	319.9	328.5	346.9	353.8	356.5	363.8	394.4	13.7	8.4	1,114.7	995.3	12.0
Revenue	21,557	23,312	24,729	24,860	24,849	25,707	28,111.0	13.7	9.4	78,667	69,598	13.0
Operating Expenditure	17,367	18,522	19,639	20,095	20,270	21,050	22,837	16.3	8.5	64,157	55,528	15.5
Cost of revenues	13,977.0	15,124.0	16,125.0	16,417.0	16,625.0	17,525.0	19,188.0	19.0	9.5	53,338	45,226	17.9
as % of sales	64.8	64.9	65.2	66.0	66.9	68.2	68.3	-	-	67.8	65.0	-
SG&A expenses	3,390.0	3,398.0	3,514.0	3,678.0	3,645.0	3,525.0	3,649.0	3.8	3.5	10,819	10,302	5.0
as % of sales	15.7	14.6	14.2	14.8	14.7	13.7	13.0	-	-	13.8	14.8	-
EBITDA	4,190	4,790	5,090	4,765	4,579	4,657	5,274	3.6	13.2	14,510	14,070	3.1
Depreciation	378.0	367.0	355.0	371.0	611.0	664.0	709.0	99.7	6.8	1,984	1,100	80.4
EBIT	3,812	4,423	4,735	4,394	3,968	3,993	4,565	(3.6)	14.3	12,526	12,970	(3.4)
Other Income	1,036.0	943.0	288.0	648.0	812.0	739.0	433.0	-	-	1,984	2,267	-
PBT	4,848	5,366	5,023	5,042	4,780	4,732	4,998	(0.5)	5.6	14,510	15,237	(4.8)
Total Tax	1,236.0	1,363.0	1,268.0	1,255.0	1,225.0	1,130.0	1,231.0	(2.9)	8.9	3,586	3,867	(7.3)
Reported PAT	3,612	4,003	3,755	3,787	3,555	3,602	3,767	0.3	4.6	10,924	11,370	(3.9)
Reported EPS	20.6	22.6	21.6	21.6	20.3	20.5	21.5	(0.6)	4.8	62.3	64.8	(3.9)
Margins (%)								(bps)	(bps)			(bps)
EBITDA	19.4	20.5	20.6	19.2	18.4	18.1	18.8	(180)	60	18.4	20.2	(180)
EBIT	17.7	19.0	19.1	17.7	16.0	15.5	16.2	(290)	70	15.9	18.6	(270)
EBT	22.5	23.0	20.3	20.3	19.2	18.4	17.8	(250)	(60)	18.4	21.9	(340)
PAT	16.8	17.2	15.2	15.2	14.3	14.0	13.4	(180)	(60)	13.9	16.3	(250)
Effective Tax rate	25.5	25.4	25.2	24.9	25.6	23.9	24.6	(60)	70	24.7	25.4	(70)

Source: Company, BOBCAPS Research

FIG 6 - DEC'19 QUARTER OPERATING METRICS

Book 1	Q3FY20	Growth		
Particulars	(% Contr. to Revenue)	Q ₀ Q (%)	Y ₀ Y (%)	
Revenue by Vertical				
BFS	27.8	11.2	8.6	
Insurance	17.8	3.2	13.7	
Manufacturing	17.5	15.7	27.5	
Energy & Process	11.3	1.2	19.0	
CPG, Retail & Pharma	11.2	5.6	20.1	
High-Tech, Media & Entertainment	10.8	8.4	8.7	
Others	3.7	14.6	(8.6)	
Revenue by Geography				
North America	69.5	9.7	18.3	
Europe	15.6	3.1	6.2	
India	7.6	37.3	10.8	
RoW	7.4	(9.9)	(4.4)	
Client Contribution to Revenue				
Top 5 clients	32.8	12.2	8.1	
Top 10 clients	46.8	11.5	9.9	
Top 20 clients	62.0	9.5	9.6	
Non top 20 client revenues	38.0	6.7	21.0	
Digital Revenues	41.0	10.3	26.0	
C C DODCADED I				



Valuation methodology

Impressive Dec'19 quarter revenues and consistent big deal wins position LTI well to reclaim its industry-wide growth leadership. We raise FY21/FY22 EPS estimates by 2%/3% to bake in higher revenue growth and increase our target P/E multiple to 20x from 19.3x to factor in the swifter-than-expected growth rebound; on rolling valuations forward, we have a new Mar'21 target price of Rs 2,230 (vs. Rs 2,010). Reiterate BUY as we like LTI's growth prospects backed by its strong sales engine, 'outcome-focused' digital capabilities, client mining skills and robust leadership.

FIG 7 - REVISED ESTIMATES

(Rs mn)		FY20E			FY21E			FY22E	
(KS mn)	Old	New	Change (%)	Old	New	Change (%)	Old	New	Change (%)
Revenues (US\$ mn)	1,474	1,521	3.2	1,641	1,744	6.3	1,833	1,956	6.7
YoY growth (%)	9.2	12.7	-	11.4	14.7	-	11.7	12.1	-
Revenues	1,03,286	1,07,103	3.7	1,14,878	1,22,099	6.3	1,28,327	1,36,908	6.7
EBITDA	19,232	19,941	3.7	22,606	23,574	4.3	25,252	26,597	5.3
EBITDA margins (%)	18.6	18.6	-	19.7	19.3	-	19.7	19.4	-
Net profits	15,082	14,971	(0.7)	17,613	17,837	1.3	19,002	19,538	2.8
EPS	85.9	85.4	(0.6)	100.3	101.8	1.5	108.3	111.5	3.0

Source: BOBCAPS Research

FIG 8 - RELATIVE STOCK PERFORMANCE



Source: NSE

Key risks

- Currency risk: Sharp fluctuation in exchange rates may materially impact the company's operating profits.
- **Leadership flux:** LTI has suffered from a leadership flux in the past (prior to FY14) a repeat of this situation would pose a risk to our thesis.
- Inability to sustain large deal momentum: Steady large deal wins are critical
 for the company to sustain its strong growth traction. An inability to do so
 may derail growth.



FINANCIALS

Income Statement

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue	73,064	94,458	1,07,103	1,22,099	1,36,908
EBITDA	11,875	18,835	19,941	23,574	26,597
Depreciation	1,563	1,471	2,695	3,052	3,423
EBIT	10,312	17,364	17,246	20,522	23,174
Net interest income/(expenses)	0	0	0	0	0
Other income/(expenses)	4,102	2,915	2,659	3,261	2,876
Exceptional items	0	0	0	0	0
EBT	14,414	20,279	19,905	23,783	26,050
Income taxes	3,290	5,122	4,935	5,946	6,513
Extraordinary items	0	0	0	0	0
Min. int./Inc. from associates	0	0	0	0	0
Reported net profit	11,124	15,157	14,971	17,837	19,538
Adjustments	0	0	0	0	0
Adjusted net profit	11,124	15,157	14,971	17,837	19,538

Balance Sheet

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Accounts payables	0	0	0	0	0
Other current liabilities	12,960	15,291	17,338	19,766	22,163
Provisions	2,123	2,402	2,724	3,105	3,481
Debt funds	0	0	0	0	0
Other liabilities	132	56	56	56	56
Equity capital	171	171	171	171	171
Reserves & surplus	38,439	48,772	57,434	67,755	79,059
Shareholders' fund	38,610	48,943	57,605	67,926	79,230
Total liabilities and equities	53,825	66,692	77,723	90,852	1,04,930
Cash and cash eq.	3,633	4,150	10,601	18,225	26,867
Accounts receivables	22,327	23,845	19,073	21,744	24,381
Inventories	0	0	0	0	0
Other current assets	7,121	10,878	13,498	15,388	17,254
Investments	12,643	17,402	17,402	17,402	17,402
Net fixed assets	5,281	8,031	8,014	8,014	8,014
CWIP	0	0	0	0	0
Intangible assets	0	0	0	0	0
Deferred tax assets, net	2,821	2,386	2,386	2,386	2,386
Other assets	0	0	6,749	7,694	8,627
Total assets	53,826	66,692	77,723	90,852	1,04,931



Cash Flows

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Net income + Depreciation	9,106	16,628	17,666	20,890	22,960
Interest expenses	134	(1,089)	(477)	(1,680)	(2,138)
Non-cash adjustments	0	0	0	0	0
Changes in working capital	(3,760)	(2,665)	(2,229)	(2,696)	(2,663)
Other operating cash flows	2,958	1,010	0	0	0
Cash flow from operations	8,438	13,884	14,960	16,513	18,160
Capital expenditures	(982)	(4,221)	(2,678)	(3,052)	(3,423)
Change in investments	(2,501)	(4,324)	0	0	0
Other investing cash flows	(1,041)	1,089	477	1,680	2,138
Cash flow from investing	(4,524)	(7,456)	(2,201)	(1,372)	(1,285)
Equities issued/Others	3	0	0	0	0
Debt raised/repaid	0	0	0	0	0
Interest expenses	(1,045)	0	0	0	0
Dividends paid	(3,034)	(5,911)	(6,309)	(7,517)	(8,233)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(4,076)	(5,911)	(6,309)	(7,517)	(8,233)
Changes in cash and cash eq.	(162)	517	6,451	7,624	8,642
Closing cash and cash eq.	3,633	4,150	10,601	18,225	26,867

Per Share

Y/E 31 Mar (Rs)	FY18A	FY19A	FY20E	FY21E	FY22E
Reported EPS	63.5	86.5	85.4	101.8	111.5
Adjusted EPS	63.5	86.5	85.4	101.8	111.5
Dividend per share	21.5	28.0	29.9	35.6	39.0
Book value per share	220.5	279.2	328.8	387.7	452.2

Valuations Ratios

Y/E 31 Mar (x)	FY18A	FY19A	FY20E	FY21E	FY22E
EV/Sales	4.6	3.5	3.1	2.7	2.4
EV/EBITDA	28.3	17.8	16.8	14.1	12.2
Adjusted P/E	30.4	22.4	22.6	19.0	17.3
P/BV	8.8	6.9	5.9	5.0	4.3

DuPont Analysis

Y/E 31 Mar (%)	FY18A	FY19A	FY20E	FY21E	FY22E
Tax burden (Net profit/PBT)	77.2	74.7	75.2	75.0	75.0
Interest burden (PBT/EBIT)	139.8	116.8	115.4	115.9	112.4
EBIT margin (EBIT/Revenue)	14.1	18.4	16.1	16.8	16.9
Asset turnover (Revenue/Avg TA)	148.9	156.8	148.3	144.9	139.9
Leverage (Avg TA/Avg Equity)	1.4	1.4	1.4	1.3	1.3
Adjusted ROAE	31.8	34.6	28.1	28.4	26.6

Source: Company, BOBCAPS Research | Note: TA = Total Assets



Ratio Analysis

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
YoY growth (%)					
Revenue	12.4	29.3	13.4	14.0	12.1
EBITDA	(3.4)	58.6	5.9	18.2	12.8
Adjusted EPS	(8.2)	36.1	(1.2)	19.1	9.5
Profitability & Return ratios (%)					
EBITDA margin	16.3	19.9	18.6	19.3	19.4
EBIT margin	14.1	18.4	16.1	16.8	16.9
Adjusted profit margin	15.2	16.0	14.0	14.6	14.3
Adjusted ROAE	31.8	34.6	28.1	28.4	26.6
ROCE	32.8	43.4	37.5	42.4	45.4
Working capital days (days)					
Receivables	85	89	73	61	61
Inventory	0	0	0	0	0
Payables	12	11	11	11	11
Ratios (x)					
Gross asset turnover	13.6	14.2	13.4	15.2	17.1
Current ratio	2.2	2.2	2.5	2.8	3.0
Net interest coverage ratio	NA	NA	NA	NA	NA
Adjusted debt/equity	(0.1)	(0.1)	(0.2)	(0.3)	(0.3)



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD - Expected return from >+5% to +15%

REDUCE - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

HISTORICAL RATINGS AND TARGET PRICE: L&T INFOTECH (LTI IN)



B - Buy, A - Add, R - Reduce, S - Sell

Rating distribution

As of 31 December 2019, out of 83 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 50 have BUY ratings, 18 are rated ADD, 9 are rated REDUCE and 6 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

L&T INFOTECH



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.